What is the appropriate management for a patient with Wolff‑Parkinson‑White syndrome presenting with a sustained heart rate of 150–160 beats per minute?

Management of WPW with Sustained HR 150-160 bpm

For a hemodynamically stable WPW patient with sustained tachycardia at 150-160 bpm, first determine the QRS width on ECG: if narrow (<120 ms), treat as orthodromic AVRT with vagal maneuvers followed by adenosine; if wide (≥120 ms indicating pre-excited AF), use IV procainamide or ibutilide—never use AV nodal blockers (beta-blockers, calcium channel blockers, digoxin, or adenosine) as these are contraindicated and can precipitate ventricular fibrillation. 1, 2

Critical First Step: Assess Hemodynamic Stability

• If hemodynamically unstable (systolic BP <80 mmHg, altered mental status, chest pain, acute heart failure): immediate synchronized electrical cardioversion 3, 1, 2
  • This is Class I recommendation to prevent ventricular fibrillation
  • Do not delay for pharmacologic therapy

For Hemodynamically Stable Patients: ECG-Guided Approach

Narrow QRS Complex (<120 ms) = Orthodromic AVRT

This indicates the accessory pathway is conducting retrograde only, making AV nodal blockade safe and effective:

1. Vagal maneuvers first (Valsalva, carotid massage) 2
2. Adenosine 6 mg rapid IV push, followed by 12 mg if needed 2
   • Safe because antegrade conduction is through the AV node
   • Will terminate the tachycardia in most cases
3. If adenosine fails: synchronized cardioversion 2

Wide QRS Complex (≥120 ms) = Pre-excited AF/Flutter

This is the dangerous scenario where the accessory pathway is conducting antegrade rapidly:

Class I Recommendations:

• IV procainamide (20-50 mg/min until arrhythmia suppressed, hypotension occurs, QRS widens >50%, or max dose 17 mg/kg) 3, 1, 2
• IV ibutilide as alternative 3, 1, 2

Class IIb (reasonable but less preferred):

• IV quinidine, disopyramide, or amiodarone 3, 1

Absolutely Contraindicated Medications (Class III)

Never administer these in WPW with wide QRS tachycardia:

• Beta-blockers (metoprolol, esmolol, etc.)
• Calcium channel blockers (diltiazem, verapamil)
• Digoxin
• Adenosine (when QRS ≥120 ms)

3, 1, 2

Why these are dangerous: They block the AV node preferentially, which paradoxically increases conduction down the accessory pathway, potentially accelerating the ventricular rate to >250 bpm and triggering ventricular fibrillation and sudden death.

Common Pitfalls to Avoid

1. Assuming all regular wide-complex tachycardias are ventricular tachycardia - In WPW, pre-excited AF can appear regular initially and mimic VT. The history of known WPW or delta waves on prior ECGs is critical.

2. Reflexively giving adenosine for any tachycardia - While adenosine is diagnostic and therapeutic for narrow-complex tachycardias, it can be dangerous in wide-complex pre-excited rhythms by unmasking rapid accessory pathway conduction 1, 2

3. Using "rate control" strategies - The goal in WPW is rhythm control (termination), not rate control. Traditional rate-controlling agents are contraindicated.

Definitive Management Discussion

After acute stabilization, discuss catheter ablation with the patient 3, 1, 2:

• Class I indication for symptomatic patients with rapid heart rates
• Success rates >95% in experienced centers
• Eliminates risk of sudden cardiac death
• Curative therapy that avoids lifelong antiarrhythmic drugs

The 2016 ACC/AHA/HRS guidelines emphasize that catheter ablation should be considered first-line therapy for symptomatic WPW patients, particularly those presenting with rapid ventricular rates or syncope 2.

Practical Algorithm Summary

WPW + HR 150-160 sustained
↓
Hemodynamically unstable? → YES → Immediate cardioversion
↓ NO
Obtain 12-lead ECG
↓
QRS <120 ms (narrow) → Vagal maneuvers → Adenosine 6-12 mg
↓
QRS ≥120 ms (wide) → IV Procainamide OR IV Ibutilide
                      AVOID: β-blockers, CCB, digoxin, adenosine
↓
If medications fail → Synchronized cardioversion
↓
After stabilization → Refer for EP study and ablation

The evidence strongly supports this algorithmic approach, with the most recent 2025 AHA guidelines 4 and 2016 ACC/AHA/HRS guidelines 2 providing the highest quality recommendations for acute management, while emphasizing that definitive treatment with catheter ablation addresses both mortality risk and quality of life.